Home » Topics » Neurology/psychiatric, BioWorld Science

Neurology/psychiatric, BioWorld Science
RSS

SIBIA Neurosciences reports preclinical results with NAChR-selective compounds

Nov. 21, 1996

NIH to conduct clinical trial of Ampalex in AD

Nov. 21, 1996

First pivotal trial for panic disorder Rx

Nov. 20, 1996

Cephalon/Leo neurological disease collaboration

Nov. 20, 1996

Antimigraine drug from Vanguard to enter pivotal trials

Nov. 20, 1996

Peripheral opiate antihyperalgesic from Adolor in clinical trials

Nov. 20, 1996

SKB reports D3-selective antipsychotic agents

Nov. 20, 1996

Analgesic kappa-opioid agonists reported by Pfizer

Nov. 20, 1996

Daiichi discloses cerebroprotective agents

Nov. 15, 1996

IL-6 as a target for Alzheimer's disease drug design

Nov. 15, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 15, 2026.
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...